DURECT Corporation (NASDAQ:DRRX) Investor Investigation Concerning Possible Violations Of Securities Laws

If you purchased shares of DURECT Corporation (NASDAQ:DRRX), you have certain options and you should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
DURECT
Affected Securities: 
NASDAQ: DRRX

May 14, 2013 (Shareholders Foundation) - An investigation on behalf of investors of DURECT Corporation (NASDAQ:DRRX) shares over potential securities laws violations by DURECT and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of DURECT Corporation (NASDAQ:DRRX) concerning whether a series of statements by DURECT regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

DURECT Corporation reported that its annual Total Revenue rose from $24.46 million in 2009 to $53.07 million in 2012 and that its Net Loss of $30.29 million in 2009 turned into a Net Income of $16.20 million in 2012.

Then on May 10, 2013, DURECT Corporation announced that Pfizer has provided an update on Remoxy.

Shares of DURECT Corporation declined from $1.64 per share on May 8, 2013, to $0.79 per share on May 10, 2013.

On May 14, 2013, NASDAQ:DRRX shares closed at $1.02 per share.